Publicaciones en colaboración con investigadores/as de University of Milan (24)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

    Journal of Cystic Fibrosis, Vol. 21, Núm. 4, pp. e221-e231

  3. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation

    Respiratory Medicine, Vol. 192

2021

  1. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

    Chest, Vol. 159, Núm. 1, pp. 58-72

  2. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study

    Journal of Cystic Fibrosis, Vol. 20, Núm. 1, pp. 25-30

  3. Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study (European Journal of Clinical Microbiology & Infectious Diseases, (2020), 39, 8, (1513-1525), 10.1007/s10096-020-03870-3)

    European Journal of Clinical Microbiology and Infectious Diseases

  4. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe

    ERJ Open Research, Vol. 7, Núm. 4

  5. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

    Journal of Cystic Fibrosis, Vol. 20, Núm. 4, pp. 566-577

  6. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  7. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study

    European Respiratory Journal, Vol. 58, Núm. 3

2020

  1. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry

    Journal of Cystic Fibrosis, Vol. 19, Núm. 3, pp. 376-383

  2. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (BMC Infectious Diseases, (2018), 18, 1, (677), 10.1186/s12879-018-3565-z)

    BMC Infectious Diseases

  3. Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)

    Respiratory Research, Vol. 21, Núm. 1

  4. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

    Journal of Cystic Fibrosis, Vol. 19, Núm. 6, pp. 868-871

  5. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts

    Pulmonology, Vol. 26, Núm. 4, pp. 233-240

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

  2. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

    Journal of Infection, Vol. 79, Núm. 4, pp. 300-311

  3. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients

    Clinical Infectious Diseases, Vol. 68, Núm. 9, pp. 1482-1493